Browsing by Author "Jahnukainen, Timo"
Now showing items 1-2 of 2
-
Suihko, Aino; Tainio, Juuso; Tuokkola, Jetta; Ylinen, Elisa; Hölttä, Tuula; Jahnukainen, Timo (2024)Background The only effective treatment for severe forms of congenital nephrotic syndrome is nephrectomy and kidney transplantation (KT). Optimal timing of nephrectomy is unclear. Methods The influence of early (Group 1, n = 13) versus delayed (Group 2, n = 10) nephrectomy on patient outcome was evaluated. The key laboratory results, growth, number of thromboembolic events and infections, KT-related complications, and eating ability after KT were compared between the two groups. Results Patients in group 1 were significantly younger at nephrectomy compared to group 2 (278 vs. 408 days, p = 0.007) and the dialysis time was significantly (p < 0.001) longer, 261 vs. 36 days, respectively. The occurrence of thromboembolic events or septicemia before KT did not differ between the groups. In group 1, eating problems and need for nasogastric tube (NGT) feeding were more common than in group 2. NGT dependency at discharge, 3 months, and 6 months post-KT were 100%, 92%, and 69% in group 1 and 90% (p = 0.244), 50% (p = 0.022), and 20% (p = 0.019) in group 2, respectively. Neurocognitive development was considered normal before KT and 12 months after the KT in 30.8% and 84.6% of the patients in group 1 and in 80% (p = 0.019) and 90% (p = 0.704) in group 2, respectively. Conclusions Infants with delayed nephrectomy seem to have comparative outcome but less infantile eating disorders and better neurocognitive development during the first post-KT months compared to infants with early nephrectomy.
-
Tiusanen, Toivo; Hukkinen, Maria; Leskinen, Outi; Soini, Tea; Kanerva, Jukka; Jahnukainen, Timo; Mäkisalo, Heikki; Heikinheimo, Markku; Pakarinen, Mikko (2019)Aim: To analyse incidence, treatment and outcomes of paediatric liver malignancies in Finland during 1987‐2017. Methods: Medical records and national cancer registry data of 47 children with liver malignancies were reviewed. Survival was calculated with the Kaplan‐Meier method. Results: During follow‐up, liver malignancy incidence remained stable at 1.1:10^6. Altogether, 42 patients with hepatoblastoma (n = 24), hepatocellular carcinoma (n = 11) and undifferentiated embryonal sarcoma (n = 7) underwent surgery at median age 4.6 (interquartile range, 2.0‐9.6) years and were followed up for 13 (7.0‐19) years. Cumulative 5‐year survival was 86% for hepatoblastoma, 41% for hepatocellular carcinoma and 67% for undifferentiated embryonal sarcoma. Five‐year survival was decreased among hepatoblastoma patients aged ≥ 2.4 years (73% versus 100%, P = .040), with PRETreatment EXTent of disease IV (PRETEXT, 60% vs 100%,P = .004), and with recurrent disease (67% vs 88%, P = .029). Recurrent/residual disease associated with decreased 5‐year survival in hepatocellular carcinoma (0% vs83%, P = .028). Survival was similar among 19 transplanted and 23 resected patients. In total, 14 deaths occurred either for the underlying malignancy (n = 8), adverse effects of chemotherapy (n = 5) or unrelated reasons (n = 1). Conclusion: Outcomes for PRETEXT I‐III hepatoblastoma and un‐metastasized hepatocellular carcinoma were encouraging. Adverse effects of chemotherapy significantly contributed to mortality.
Now showing items 1-2 of 2